NuVision Biotherapies
Latest round
- Seed
Last raised
- Jul 2015
Total raised
- $0.6M
Investors
- 1
About NuVision Biotherapies
NuVision Biotherapies Limited develops innovative ocular therapies, focusing on advanced products for eye care professionals to enhance healing and treatment options for ocular surface diseases. Founded in 2015 by founder Andrew Hopkinson in Nottingham, UK, NuVision Biotherapies Limited specializes in ocular therapies. NuVision Biotherapies specializes in innovative ocular therapies, primarily focusing on two key product offerings: Omnigen and OmniLenz. Omnigen is a wound dressing and grafting material derived from amniotic membrane, designed to provide a natural barrier that supports healing for ocular surface diseases and injuries. The product retains the membrane's essential barrier functions through a proprietary processing method, ensuring that it can be conveniently stored and accessed in a range of clinical settings. OmniLenz, on the other hand, presents a bespoke contact lens solution aimed at delivering rapid care without the need for surgical intervention. These products are primarily targeted towards eye care specialists and clinicians, serving a diverse clientele that includes hospitals, outpatient clinics, and private practices across Europe and North America. By addressing the urgent need for effective and accessible ocular care, NuVision Biotherapies is positioning itself to cater to the growing demand for advanced treatments in the ophthalmology sector. NuVision Biotherapies generates revenue through direct sales of its flagship products, Omnigen and OmniLenz, to healthcare providers within the ophthalmology market. The company operates on a business-to-business (B2B) model, where transactions occur primarily between NuVision and its clients, including hospitals and eye care clinics. These transactions typically involve bulk orders of products tailored to the specific needs of the eye care professionals, allowing for a streamlined supply chain. While specific pricing details for these offerings are not disclosed, it is understood that the sales structure may involve negotiated contracts that take into account the volume and frequency of orders. Through these established relationships, NuVision Biotherapies aims to sustain recurring revenue from its innovative therapies, thereby supporting its ongoing mission to enhance ocular health outcomes globally.
Who invested in NuVision Biotherapies
1 investor across 1 round
See all investors in NuVision Biotherapies
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
Jul 14, 2015
Amount
$0.6M
Investors
Questions about NuVision Biotherapies
Who invested in NuVision Biotherapies?
NuVision Biotherapies has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has NuVision Biotherapies raised?
NuVision Biotherapies has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did NuVision Biotherapies last raise money?
NuVision Biotherapies's most recent round on record is a Seed, in Jul 2015.
What does NuVision Biotherapies do?
NuVision Biotherapies Limited develops innovative ocular therapies, focusing on advanced products for eye care professionals to enhance healing and treatment options for ocular surface diseases.
Where is NuVision Biotherapies headquartered?
NuVision Biotherapies is headquartered in Nottingham, UK.
Which VCs invest in companies like NuVision Biotherapies?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Balderton Capital back biotechnology companies at NuVision Biotherapies's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like NuVision Biotherapies? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.